Back in my grad school days, I collaborated on some ABCA1/HDL research with Dr. Cheryl Wellington and Dr. Michael Hayden as part of a collaboration between University of Wisconsin with University of British Columbia and Xenon Pharmaceuticals (which coincidentally is doing quite well this year; XENE). Cheryl is one of the chairs of the Gordon Conference. She currently has a strong interest in HDL and neurodegenerative diseases such as Alzheimer's disease. She even published a review a few years back mentioning the potential promise of RVX-208 (apabetalone) for modulating Alzheimer's disease pathogenesis due to its ability to increase apoAI/HDL and also increase circulating amyloid beta 40 (AB40) levels. The latter of which is inferred to be due to the release of Aβ40 from the brain. Hopefully some good discussion going on between Dr. Wong, Dr. Wellington and others.

BDAZ